CA2773125A1 - Compounds having tafia inhibitory activity - Google Patents
Compounds having tafia inhibitory activity Download PDFInfo
- Publication number
- CA2773125A1 CA2773125A1 CA2773125A CA2773125A CA2773125A1 CA 2773125 A1 CA2773125 A1 CA 2773125A1 CA 2773125 A CA2773125 A CA 2773125A CA 2773125 A CA2773125 A CA 2773125A CA 2773125 A1 CA2773125 A1 CA 2773125A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- dihydroimidazo
- quinolin
- chloroform
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009215093 | 2009-09-17 | ||
| JP2009-215093 | 2009-09-17 | ||
| JP2010103546 | 2010-04-28 | ||
| JP2010-103546 | 2010-04-28 | ||
| PCT/JP2010/066637 WO2011034215A1 (en) | 2009-09-17 | 2010-09-17 | COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2773125A1 true CA2773125A1 (en) | 2011-03-24 |
Family
ID=43758807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2773125A Abandoned CA2773125A1 (en) | 2009-09-17 | 2010-09-17 | Compounds having tafia inhibitory activity |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120172598A1 (enExample) |
| EP (1) | EP2477989A4 (enExample) |
| JP (1) | JP2013505202A (enExample) |
| AR (1) | AR078424A1 (enExample) |
| AU (1) | AU2010296312A1 (enExample) |
| CA (1) | CA2773125A1 (enExample) |
| IN (1) | IN2012DN01966A (enExample) |
| NZ (1) | NZ598478A (enExample) |
| PH (1) | PH12012500526A1 (enExample) |
| SG (1) | SG179176A1 (enExample) |
| TW (1) | TW201121964A (enExample) |
| WO (1) | WO2011034215A1 (enExample) |
| ZA (1) | ZA201201528B (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003013526A1 (en) * | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
| BR0307033A (pt) * | 2002-01-22 | 2004-12-07 | Pfizer | ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas |
| WO2010050525A1 (ja) * | 2008-10-29 | 2010-05-06 | 大正製薬株式会社 | ＴＡＦＩａ阻害活性を有する化合物 |
-
2010
- 2010-09-16 AR ARP100103378A patent/AR078424A1/es not_active Application Discontinuation
- 2010-09-16 TW TW099131555A patent/TW201121964A/zh unknown
- 2010-09-17 US US13/496,625 patent/US20120172598A1/en not_active Abandoned
- 2010-09-17 EP EP10817326A patent/EP2477989A4/en not_active Withdrawn
- 2010-09-17 CA CA2773125A patent/CA2773125A1/en not_active Abandoned
- 2010-09-17 PH PH1/2012/500526A patent/PH12012500526A1/en unknown
- 2010-09-17 NZ NZ598478A patent/NZ598478A/xx not_active IP Right Cessation
- 2010-09-17 WO PCT/JP2010/066637 patent/WO2011034215A1/en not_active Ceased
- 2010-09-17 IN IN1966DEN2012 patent/IN2012DN01966A/en unknown
- 2010-09-17 AU AU2010296312A patent/AU2010296312A1/en not_active Abandoned
- 2010-09-17 JP JP2012506827A patent/JP2013505202A/ja not_active Withdrawn
- 2010-09-17 SG SG2012018644A patent/SG179176A1/en unknown
-
2012
- 2012-02-29 ZA ZA2012/01528A patent/ZA201201528B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2477989A4 (en) | 2013-03-13 |
| IN2012DN01966A (enExample) | 2015-08-21 |
| AU2010296312A1 (en) | 2012-03-29 |
| TW201121964A (en) | 2011-07-01 |
| AR078424A1 (es) | 2011-11-09 |
| SG179176A1 (en) | 2012-04-27 |
| EP2477989A1 (en) | 2012-07-25 |
| ZA201201528B (en) | 2013-05-29 |
| PH12012500526A1 (en) | 2012-10-22 |
| US20120172598A1 (en) | 2012-07-05 |
| WO2011034215A1 (en) | 2011-03-24 |
| NZ598478A (en) | 2013-01-25 |
| JP2013505202A (ja) | 2013-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2655914C2 (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| TWI668224B (zh) | Phosphonium derivative, preparation method and use thereof | |
| AU2014338947B2 (en) | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | |
| KR102634308B1 (ko) | 피롤로피리미딘 화합물 | |
| KR102090780B1 (ko) | 혈전색전성 질환의 치료를 위한 인자 ｘｉａ 억제제로서 치환된 피롤리딘 | |
| EA029521B1 (ru) | Производные 1-амино-2-циклопропилэтилбороновой кислоты | |
| CN102118969A (zh) | 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂 | |
| JPWO1998009949A1 (ja) | 新規アセトアミド誘導体およびプロテアーゼ阻害剤 | |
| CN113614095B (zh) | 作为精氨酸酶抑制剂的烷基硼酸类化合物 | |
| WO2024199266A1 (en) | Compounds for degradation and inhibition of kras (g12d) protein | |
| WO2014146494A1 (zh) | β-氨基羰基类化合物、其制备方法、药物组合物及其用途 | |
| JP2023168413A (ja) | オキソ置換化合物 | |
| HUE029976T2 (en) | New substituted isoquinoline derivatives | |
| AU2009310841A1 (en) | Compounds having TAFIa inhibitory activity | |
| WO2011025799A1 (en) | Cathepsin c inhibitors | |
| CA2773125A1 (en) | Compounds having tafia inhibitory activity | |
| HK1248227A1 (zh) | 酚噻嗪化合物及其用途 | |
| JP2012207016A (ja) | ＴＡＦＩａ阻害活性を有する化合物を有効成分として含有する抗血栓剤 | |
| EP4077283A1 (en) | Progranulin modulators and methods of using the same | |
| CN113825542A (zh) | 精氨酸牙龈蛋白酶抑制剂 | |
| TW202537962A (zh) | 抑制α-V β-1整合素 | |
| WO2023240379A1 (zh) | 咪唑啉酮衍生物及其用途 | |
| CN121064264A (zh) | 糖基化邻苯二甲酰亚胺类化合物、其制备方法及其用途 | |
| WO2014025658A1 (en) | Pyrrolidine thrombin inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20150917 |